Aethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird Flu
Aethlon Medical (NASDAQ: AEMD) has provided an update on its investigational Hemopurifier device's capability to capture H5N1 Bird Flu virus. The update comes amid rising concerns over Bird Flu cases in dairy cows and humans across eight states, including a severe case in Louisiana and California's state of emergency declaration.
Laboratory tests at Battelle labs demonstrated that a miniature version of the Hemopurifier removed 99% of H5N1 after 6 hours of treatment in vitro. The device, which removes enveloped viruses from bloodstream, has been used in 38 patients across 164 treatment sessions for various diseases including hepatitis C, HIV, COVID-19, and Ebola. The Hemopurifier holds FDA 'breakthrough device' designation for life-threatening viruses lacking effective treatments.
Aethlon Medical (NASDAQ: AEMD) ha fornito un aggiornamento sulla capacità del suo dispositivo investigativo Hemopurifier di catturare il virus H5N1 dell'influenza aviaria. L'aggiornamento arriva in un momento di crescenti preoccupazioni per i casi di influenza aviaria in mucche da latte e esseri umani in otto stati, inclusi un caso grave in Louisiana e la dichiarazione di stato d'emergenza in California.
I test di laboratorio presso i laboratori Battelle hanno dimostrato che una versione in miniatura dell'Hemopurifier ha rimosso il 99% dell'H5N1 dopo 6 ore di trattamento in vitro. Il dispositivo, che rimuove i virus avvolti dal flusso sanguigno, è stato utilizzato in 38 pazienti in 164 sessioni di trattamento per varie malattie tra cui epatite C, HIV, COVID-19 ed Ebola. L'Hemopurifier ha ricevuto la designazione di 'dispositivo innovativo' dalla FDA per virus potenzialmente letali privi di trattamenti efficaci.
Aethlon Medical (NASDAQ: AEMD) ha proporcionado una actualización sobre la capacidad de su dispositivo investigativo Hemopurifier para capturar el virus H5N1 de la gripe aviar. La actualización llega en medio de crecientes preocupaciones por casos de gripe aviar en vacas lecheras y humanos en ocho estados, incluido un caso severo en Luisiana y la declaración de estado de emergencia en California.
Las pruebas de laboratorio en los laboratorios Battelle demostraron que una versión en miniatura del Hemopurifier eliminó el 99% del H5N1 después de 6 horas de tratamiento in vitro. El dispositivo, que elimina virus envueltos del torrente sanguíneo, ha sido utilizado en 38 pacientes a través de 164 sesiones de tratamiento para diversas enfermedades, incluyendo hepatitis C, VIH, COVID-19 y Ébola. El Hemopurifier tiene la designación de 'dispositivo innovador' de la FDA para virus que amenazan la vida y carecen de tratamientos efectivos.
Aethlon Medical (NASDAQ: AEMD)는 조류 독감 H5N1 바이러스를 포획할 수 있는 실험적 Hemopurifier 장치에 대한 업데이트를 제공했습니다. 이 업데이트는 루이지애나의 심각한 사례와 캘리포니아의 비상 사태 선언을 포함하여 8개 주에서 유제품 소 및 인간에서 조류 독감 사례에 대한 우려가 커지는 가운데 이루어졌습니다.
배틀 연구소에서 실시한 실험실 테스트 결과, Hemopurifier의 소형 버전이 인 비트로 치료 후 6시간 만에 99%의 H5N1을 제거한 것으로 나타났습니다. 이 장치는 혈류에서 감싸인 바이러스를 제거하며, 간염 C, HIV, COVID-19 및 에볼라를 포함한 다양한 질병에 대해 164회의 치료 세션에서 38명의 환자에게 사용되었습니다. Hemopurifier는 효과적인 치료법이 없는 생명을 위협하는 바이러스에 대해 FDA의 '혁신적 장치' 지정을 받았습니다.
Aethlon Medical (NASDAQ: AEMD) a fourni une mise à jour sur la capacité de son dispositif expérimental Hemopurifier à capturer le virus de la grippe aviaire H5N1. Cette mise à jour intervient au milieu des préoccupations croissantes concernant les cas de grippe aviaire chez les vaches laitières et les humains dans huit États, y compris un cas grave en Louisiane et la déclaration d'état d'urgence en Californie.
Des tests en laboratoire réalisés dans les laboratoires Battelle ont démontré qu'une version miniature de l'Hemopurifier a éliminé 99% de H5N1 après 6 heures de traitement in vitro. Le dispositif, qui élimine les virus enveloppés du flux sanguin, a été utilisé chez 38 patients au cours de 164 séances de traitement pour diverses maladies, y compris l'hépatite C, le VIH, le COVID-19 et Ebola. L'Hemopurifier a obtenu de la FDA la désignation de 'dispositif révolutionnaire' pour les virus menaçants sans traitements efficaces.
Aethlon Medical (NASDAQ: AEMD) hat ein Update zur Fähigkeit seines investigativen Hemopurifier-Geräts zur Auffangung des H5N1-Vogelgrippevirus bereitgestellt. Dieses Update kommt inmitten wachsender Bedenken über Vogelgrippefälle bei Milchkühen und Menschen in acht Bundesstaaten, einschließlich eines schweren Falls in Louisiana und der Notstandserklärung in Kalifornien.
Labortests in den Battelle-Labors haben gezeigt, dass eine Miniaturversion des Hemopurifiers 99% des H5N1-Virus nach 6 Stunden In-vitro-Behandlung entfernt hat. Das Gerät, das umhüllte Viren aus dem Blutkreislauf entfernt, wurde bei 38 Patienten in 164 Behandlungs-Sitzungen für verschiedene Krankheiten eingesetzt, darunter Hepatitis C, HIV, COVID-19 und Ebola. Der Hemopurifier hat von der FDA die Auszeichnung 'Durchbruchgerät' für lebensbedrohliche Viren ohne wirksame Behandlungen erhalten.
- Hemopurifier demonstrated 99% H5N1 virus removal efficiency in laboratory testing
- Device has FDA breakthrough designation for life-threatening viruses
- Successfully used in 38 patients across 164 treatment sessions for various diseases
- Hemopurifier has not been tested on H5N1 patients yet
- Product still in investigational phase, not FDA approved
Insights
The Hemopurifier's ability to capture 99% of H5N1 virus in vitro testing represents a potentially important development amid rising bird flu concerns. The device's mechanism, utilizing GNA lectin binding to target mannose sugars on viral surfaces, demonstrates a unique approach that could circumvent the resistance issues seen with conventional antivirals like Oseltamivir.
The 164 treatment sessions across 38 patients for various viral infections provide valuable safety data, though the lack of specific H5N1 clinical experience is a significant limitation. The FDA breakthrough designation adds regulatory credibility but doesn't guarantee efficacy against bird flu. Think of the Hemopurifier as a mechanical viral filter - while promising in lab tests, its real-world effectiveness against H5N1 remains unproven.
With a micro-cap valuation of just
Aethlon has recently received a number of inquiries regarding the potential utility of its Hemopurifier device in the treatment of Bird Flu. These inquiries come on the heels of the reporting of isolation of Bird Flu in dairy cows, 60 human cases in eight states including a case of severe infection in
The Aethlon Hemopurifier is an investigational extracorporeal medical device designed to remove enveloped viruses and extracellular vesicles from the bloodstream. The device incorporates plasma separation, size exclusion, and affinity binding to a proprietary resin containing the plant lectin Galanthus nivalis agglutinin (GNA) bound to a medical grade diatomaceous earth. Enveloped viruses and extracellular vesicles contain the sugar mannose on their surface, which is the therapeutic target of the GNA.
Aethlon has previously contracted Battelle labs to examine the in vitro removal of influenza viruses including H5N1 by a scaled down version of the Aethlon Hemopurifier. In this experiment, cell culture media was spiked with the H5N1 virus and continuously circulated over the device. Samples were taken periodically to examine viral removal by the device. In this study, a miniature version of the device removed
While the Aethlon Hemopurifier has not yet been used to treat patients with severe influenza, including those infected with H5N1, it has been used in 38 patients across 164 distinct treatment sessions, targeting diseases such as hepatitis C, HIV, and in patients critically ill due to COVID-19 and Ebola. The Hemopurifier has a "breakthrough device" designation with the FDA for life-threatening viruses for which there is no effective treatment.
Current treatment guidelines from the Center for Disease Control and Prevention (https://www.cdc.gov/bird-flu/hcp/novel-av-treatment-guidance/), for hospitalized patients with suspected Bird Flu (H5N1), are to initiate antiviral therapy as soon as possible with Oseltamivir, with or without combination therapy with Baloxavir. Clinical failures during Oseltamavir therapy due to the development of antiviral resistance have been observed in hospitalized patients with H5N1. This phenomenon raises the possibility that novel treatment strategies may be required. Aethlon Medical will monitor this situation closely and interact with hospitals, the state of
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful extracellular vesicles from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where extracellular vesicles may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a
Additional information can be found at www.AethlonMedical.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such include, without limitation, the ability of the Hemopurifier to capture H5N1 Bird Flu; the possibility of novel treatment strategies; the efficacy of the Hemopurifier and virus removal after various treatment times; the use and efficacy of the Hemopurifier being utilized in treatment session for patients with hepatitis C, HIV, as well in patients with critical illness due to COVID-19 and Ebola; the occurrence and possible continuation of the state of emergency declaration in
Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/aethlon-medical-provides-update-on-the-ability-of-its-hemopurifier-to-capture-h5n1-bird-flu-302337126.html
SOURCE Aethlon Medical, Inc.
FAQ
What are the H5N1 removal capabilities of AEMD's Hemopurifier device?
How many patients has AEMD's Hemopurifier been used on so far?
What is the current FDA status of AEMD's Hemopurifier?
Has AEMD's Hemopurifier been used to treat H5N1 Bird Flu patients?
What triggered AEMD's update on Hemopurifier's H5N1 capabilities?
